320 MATV · NYSE
$12.07 -1.51% (-$0.19)
Summary
51 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Revenue grew by 6.7% a year over the last 3 years.
What to watch
- Operating profit does not even cover the interest on its debt.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 6.7% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 82 USD
- Research and development 1.1 USD
- Sales and administration 13 USD
- Taxes and other -0.9 USD
- Net profit 4.5 USD
Net profit, industry median (Chemicals - Specialty) 5.9 USD
Out of every 100 USD of revenue, 4.5 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 8.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, safe- Yield
- 3.26%
- Paid out of profit
- 25%
You receive $0.40 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 2
- Sell 0
No analyst has published a price target.
71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- Royalty 100%
By region
- Europe 59%
- Asia Pacific 24%
- Americas, Excluding United States 12%
- Other Foreign Countries 5.6%
Royalty brings in 100% of revenue.
Segments in detail